1887

n Cardiovascular Journal of South Africa - FDA approves losartan for stroke prevention in hypertensive patients with LVH : drug trends in cardiology

USD

 

Abstract

Extracted from text ... 176 CARDIOVASCULAR JOURNAL OF SOUTH AFRICA Vol 16, No. 3, May/June 2005 FDA approves losartan for stroke prevention in hypertensive patients with LVH Losartan (Cozaar Comp(r)) has recently been approved by the FDA for the reduction of risk of stroke in patients with hypertension and left ventricular hypertrophy. The new indication for reduc tion in stroke is based on the landmark LIFE (Losartan Intervention for Endpoint Reduction in Hypertension) study.1 Cozaar Comp(r) (losartan potassium- hydrochlorothiazide tablets) and Cozaar are the only angiotensin II receptor blockers (ARBs) to be indicated for stroke reduction in this setting. Cozaar Comp(r) is the fixed-dose combination ..

Loading

Article metrics loading...

/content/cardio/16/3/EJC23999
2005-05-01
2016-12-05
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error